Beyond Monotherapy: Targeting the Triad of Insulin Resistance, Hyperandrogenism and Obesity in Polycystic Ovary Syndrome
AACE Endocrinology and Diabetes · 2026-05 · 13 (3) · 473-480
DOI: 10.1016/j.aed.2026.02.008 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift AACE Endocrinology and Diabetes, 2026-05. Verfasst von Amal Shaharyar und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Endocrinology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
- Department of Endocrinology and Metabolism, Dr RPGMC, Kangra, India.
Zitieren
APA
Shaharyar, A., Chaudhary, S., Jha, V., Bhadada, S. K., & Walia, R. (2026). Beyond Monotherapy: Targeting the Triad of Insulin Resistance, Hyperandrogenism and Obesity in Polycystic Ovary Syndrome. AACE Endocrinology and Diabetes, 13(3), 473-480. https://doi.org/10.1016/j.aed.2026.02.008
Vancouver
Shaharyar A, Chaudhary S, Jha V, Bhadada SK, Walia R. Beyond Monotherapy: Targeting the Triad of Insulin Resistance, Hyperandrogenism and Obesity in Polycystic Ovary Syndrome. AACE Endocrinology and Diabetes. 2026;13(3):473-480. doi:10.1016/j.aed.2026.02.008
BibTeX
@article{Shaharyar2026,
author = {Shaharyar, Amal and Chaudhary, Shakun and Jha, Vivek and Bhadada, Sanjay Kumar and Walia, Rama},
title = {Beyond Monotherapy: Targeting the Triad of Insulin Resistance, Hyperandrogenism and Obesity in Polycystic Ovary Syndrome},
journal = {AACE Endocrinology and Diabetes},
year = {2026},
volume = {13},
number = {3},
pages = {473--480},
doi = {10.1016/j.aed.2026.02.008}
}
EUVIMED